Cells and Materials


In this double blind study, seven out of fourteen patients who had received a cementless hydroxyapatitecovered hip prosthesis were given calcitriol (1 p.g daily), and seven an inert placebo for a period of four months. At the end of this period, total body bone densitometry (TBBD) and absorptiometric measurements in the regions of interest (ROIs) close to the prosthesis and in the opposite femur revealed that the TBBD values had decreased in the patients receiving placebo and increased in those receiving calcitriol. Furthermore, bone mineral density in the ROis had increased on the non-operated side of the calcitriol-treated patients (although to a lesser extent in the calcitriol-treated group).